Overview Of Programs Underway With The Sanguine Corporation

Sanguine Corporation (OTC Bulletin Board: SGNC), is a bio-pharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion.  The Company’s current product, PHER-O2 is a second generation to the previously FDA approved Fluosol DA product.  The goal is to replace the current product used for transporting living tissue, known as UW (University of Wisconsin) solution (trade name: Viaspan™). The availability of vital organs for transplant is severely limited, in part, because the systems most commonly used to preserve living tissue are based on 50-60 year old technologies and remain limited in their usefulness. As a result, organ banks do not have the true capability of storing organs for any significant length of time.  The benefit of transporting the living tissue in an Oxygenated bath is believe to significantly better the current technology available.  Once FDA approval is achieved, Sanguine believes that PHER-O2 will be used in a variety of ways, similar to Fluosol.

Additional Usage Known for PHER-O2

Transfusion
Transfusions represent the greatest market potential for PHER-O2. It is estimated that nearly every American who reaches the age of seventy-five will need blood, plasma, or one of their components at least once in his lifetime. U.S. blood banks supply enough blood for about 16,000,000 transfusions per year. There is a critical lack of supply of healthy blood for transfusions, with current worldwide supply for transfusions at 100,000,000 pints per year, and current worldwide demand for non-infected blood up to 300,000,000 pints per year. At current pricing, the market value of the current supply is about $18 billion per year, and the potential value of current demand is worth as much as $54 billion per year.

Heart Attack
The heart can suffer serious damage in the event of a heart attack due to poor oxygenation of obstructed regions of the myocardium. So small that it can bypass a blockage and perfuse the myocardium, perfluorocarbons offer significant hope for improving the mortality rate of heart attack victims. In the U.S. alone there are about 1,500,000 cases per year, 750,000 of which result in death before the victim even reaches the hospital. Upon arrival at the hospital up to two hours may elapse before type and cross-match are determined for a transfusion. With PHER-O2 immediate transfusion in the home or in the ambulance is a possibility for improving the chances of survival.

Stroke
The brain can suffer serious damage in the event of a stroke, also, due to poor oxygenation of obstructed regions of the brain. Again, through administration of PHER-O2 stroke victims have a greater chance of survival and recovery. The tiny micelles of PHER-O2 are able to penetrate into the areas of the brain where clotting and plaque buildup may have occurred, providing vital oxygen to the cells of the brain.

Cardioplegia
Each open-heart procedure requires the use of a machine which recycles and cleans the patient’s own blood. As the procedure takes place, high quantities of blood are expelled from the incision areas, which contact other internal anatomy, and are exposed to air and other potential contaminants or activators. When blood leaves its vascular confinement, it changes, becoming unfit for perfusion. Thus, the blood must be recycled with the heart-lung machine, and returned to the body, where the blood can properly serve its circulatory functions. The heart-lung machine must be primed with up to four pints of blood before it can be used to process the patient’s blood.

With over 300,000 open-heart procedures per year, there is a demand of up to 1,200,000 pints of precious blood for priming alone. PHER-O2 can be available for immediate use, without the need of blood typing, and without the further aggravation of allergic reaction associated with human blood, or toxicity associated with other blood substitutes.

Cancer
There is yet little hope for cures to cancers of the head and neck region, which are very difficult to treat, due to their proximity to vital organs. While oxygen is essential to life, it is toxic to life at high concentrations, due to oxygen tension. PHER-O2 has demonstrated the ability to kill cancer cells, when administered at toxic concentrations to localized areas. Tumors can be detected, oxygenated and reduced or destroyed by administering PHER-O2 locally without the deleterious side effects of chemotherapy. PHER-O2 can also target cancer with chemotherapy by adding chemotherapeutic drugs to PHER-O2 to carry the drug directly to the site of the malignancy and reduce the damage to the rest of the body.

Imaging
NMR, CT Scan, x-ray technology requires an infusion of a traceable fluid for imaging. Alliance currently markets a product called ImagentÒ, which is a PFC-based compound that can be infused into the patient for imaging purposes. PHER-O2 exhibits properties similar to Imagent, and may be a candidate for imaging use, as well.

Other Medical Applications
Sanguine’s technology is applicable to uses where oxygenation is a need or concern. One of the greatest potentials for the technology is in the treatment of Alzheimer’s Disease (AD). Data indicates that AD may be a disease resulting from oxygen deficiency due to the poor microcirculation and presence of amyloid plaques in the brain. An article by Dr. William Regelson published in the Annals of the New York Academy of Sciences in 1997 specifically hypothesizes the potential of PFCs to oxygenate plaque-encased regions of the brain to alleviate the symptoms of AD.

PHER-O2 may also be used to treat fungal and bacterial infections of the skin and gastrointestinal infections. When cells, bacteria and fungi are exposed to high concentrations of PHER-O2 the cells die due to oxygen tension. PHER-O2 may have application in the treatment of tumors, wherein the tumors are injected with oxygen rich PHER-O2 to cause the tumor cells to die.

PHER-O2 may also be an ideal treatment for oxygen-deficiency conditions, such as sickle cell crises, carbon monoxide poisoning, hemolytic anemia, and bone marrow failure or suppression.

[top]